QVR’s Vertex Pharmaceuticals VRTX Stock Holding History

QVR’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-253	Closed	-$115K	–	218
2025 Q4	$115K	Buy	+253	New	+$109K	0.01%	108
2022 Q3	–	Sell	-54	Closed	-$15.5K	–	355
2022 Q2	$15K	Buy	+54	New	+$14.5K	﹤0.01%	329

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

QVR's VRTX Position: Q1 2026 in Review

QVR sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 253 shares — an estimated $115K sold.

QVR first reported a position in VRTX in Q2 2022 and held it in 2 quarters. The position peaked at $115K in Q4 2025. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

QVR reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
QVR sold 253 Vertex Pharmaceuticals shares in Q1 2026, an estimated $115K.
QVR first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 2 quarters.
QVR's Vertex Pharmaceuticals position peaked at $115K in Q4 2025.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on QVR's 13F filing for Q1 2026, filed 15 Apr 2026.